


Table S1. Five-year conditional overall survival and failure-free survival probabilities of all patients for different risk groups over time (N=384).

	Time since treatment				
	1 year	2 year	3 year	4 year	5 year
All patients					
5-year COS (%)	87	88	92	92	94
95%CI (%)	81-92	82-93	86-96	81-97	81-98
5-year CFFS (%)	85	90	94	93	96
95%CI (%)	79-90	84-94	88-97	79-98	75-99
Early-stage patients					
5-year COS (%)	94	94	97	95	95
95%CI (%)	88-97	88-97	91-99	68-99	68-99
5-year CFFS (%)	93	96	97	92	94
95%CI (%)	86-96	88-98	89-99	67-98	63-99
Early-stage with favorable factors					
5-year COS (%)	97	98	98	100	100
95%CI (%)	86-99	86-100	86-100	100-100	100-100
5-year CFFS (%)	96	96	97	100	100
95%CI (%)	83-99	83-99	83-100	100-100	100-100
Early-stage with unfavorable factors					
5-year COS (%)	92	92	96	93	93
95%CI (%)	82-96	82-96	86-99	59-99	59-99
5-year CFFS (%)	90	96	97	88	91
95%CI (%)	79-95	83-99	81-100	55-97	51-99

Advanced-stage patients					
5-year COS (%)	81	83	88	92	95
95%CI (%)	70-89	71-90	75-94	79-97	80-99
5-year CFFS (%)	76	84	91	96	100
95%CI (%)	65-84	72-91	79-96	83-99	100-100
Low IPS score (<3)					
5-year COS (%)	95	96	96	96	96
95%CI (%)	77-99	74-100	74-100	74-100	74-100
5-year CFFS (%)	89	95	100	100	100
95%CI (%)	77-95	83-99	100-100	100-100	100-100
High IPS score (≥3)					
5-year COS (%)	64	64	72	78	87
95%CI (%)	44-78	44-79	50-85	54-91	57-97
5-year CFFS (%)	61	69	75	81	100
95%CI (%)	42-75	48-83	52-88	57-93	100-100
Patients with CR					
5-year COS (%)	93	80	89	91	92
95%CI (%)	86-97	62-90	68-96	71-97	71-98
Patients with PR					
5-year COS (%)	78	93	95	91	92
95%CI (%)	60-88	86-97	88-98	73-97	72-98
Patients with no response					
5-year COS (%)	66	70	74	88	100
95%CI (%)	36-84	37-88	38-91	39-98	100-100


Figure S1. The structure of patients in year-fashion accrual (N=384).



Male	13	18	10	8	15	33	23	33	40	6
Female	13	7	10	16	17	16	13	29	23	23

Figure S2. Conditional overall survival and death hazard estimates stratified by treatment response (N=384).


A 5-year COS



No. at risk

CR	274	251	194	140	110	23
PR	71	64	60	41	27	20
no response	39	37	24	16	10	5

B Death hazard




No. at risk

CR	274	194	110	73	31	5
PR	71	60	27	17	9	3
no response	39	24	16	4	4	1

A: 5-year COS is the 5-year conditional overall survival over time of patients who achieved complete remission (CR), partial remission (PR), or failed to respond (no response). B: Smoothed plots of the hazard estimates of death over time in patients with CR, PR, and no response.

Figure S3. Conditional survival of patients stratified by stages and risk groups under different treatment regimens.


A 5-year COS of early-stage unfavorable



No. at risk

ABVD	101	89	72	50	29	18
BEACOPP	22	22	21	19	17	16


B 5-year CFFS of early stage unfavorable



No. at risk

ABVD	101	74	56	39	25	16
BEACOPP	22	18	16	15	14	13


C 5-year COS of advanced-stage



No. at risk

ABVD	134	125	89	53	41	20
BEACOPP	32	29	29	25	27	25


D 5-year CFFS of advanced-stage



No. at risk

ABVD	134	97	34	67	41	31
BEACOPP	32	23	21	20	20	19


E 5-year COS of advanced-stage with BEACOPP



No. at risk

Low IPS	16	13	13	13	13	13
High IPS	16	16	16	14	12	10

F 5-year CFFS of advanced-stage with BEACOPP



No. at risk

Low IPS	16	12	12	11	11	11
High IPS	16	11	9	9	9	8

A: 5-year COS is the 5-year conditional overall survival over time of early-stage patients with unfavorable factors treated with ABVD or BEACOPP regimens. B: 5-year CFFS is the 5-year

conditional failure-free survival over time of early-stage patients with unfavorable factors treated with ABVD or BEACOPP regimens (Error bars denote 95% CIs). C: 5-year COS is the 5-year conditional overall survival over time of advanced-stage patients treated with ABVD or BEACOPP regimens, D: 5-year CFFS is the 5-year conditional failure-free survival over time of advanced-stage patients treated with ABVD or BEACOPP regimens (Error bars denote 95% CIs). E: 5-year COS is the 5-year conditional overall survival over time of advanced-stage patients who received the BEACOPP regimen according to IPS score. F: 5-year CFFS is the 5-year conditional failure-free survival over time of advanced-stage patients who received the BEACOPP regimen according to IPS score.